Pandemic progress in Kenya By the end of July 2020, Kenya h ad reported only 341 deaths and ∼20,000 cases of COVID-19. This is in marked contrast to the tens of thousands of deaths reported in many higher-income countries. The true extent of COVID-19 in the community was unknown and likely to be higher than reports indicated. Uyoga et al. found an overall seroprevalence among blood donors of 4.3%, peaking in 35- to 44-year-old individuals (see the Perspective by Maeda and Nkengasong). The low mortality can be partly explained by the steep demographics in Kenya, where less than 4% of the population is 65 or older. These circumstances combine to result in Kenyan hospitals not currently being overwhelmed by patients with respiratory distress. However, the imposition of a strict lockdown in this country has shifted the disease burden to maternal and child deaths as a result of disruption to essential medical services. Science, this issue p. 79; see also p. 27 By May 2020, 1 in 20 Kenyan adults had SARS-CoV-2 antibodies, when fewer than 100 COVID-19 deaths had been reported nationally. The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020, and an overwhelming number of cases and deaths were expected, but by 31 July 2020, there were only 20,636 cases and 341 deaths. However, the extent of SARS-CoV-2 exposure in the community remains unknown. We determined the prevalence of anti–SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April–June 2020. Crude seroprevalence was 5.6% (174 of 3098). Population-weighted, test-performance-adjusted national seroprevalence was 4.3% (95% confidence interval, 2.9 to 5.8%) and was highest in urban counties Mombasa (8.0%), Nairobi (7.3%), and Kisumu (5.5%). SARS-CoV-2 exposure is more extensive than indicated by case-based surveillance, and these results will help guide the pandemic response in Kenya and across Africa.

中文翻译：

---

肯尼亚献血者中抗 SARS-CoV-2 IgG 抗体的血清阳性率


肯尼亚疫情进展 截至 2020 年 7 月，肯尼亚仅报告了 341 人死亡和约 20,000 例 COVID-19 病例。这与许多高收入国家报告的数万人死亡形成鲜明对比。社区中 COVID-19 的真实情况尚不清楚，并且可能比报告显示的要高。乌瑜伽等人。研究发现，献血者的总体血清阳性率为 4.3%，在 35 至 44 岁的个体中达到顶峰（参见 Maeda 和 Nkengasong 的观点）。死亡率低的部分原因是肯尼亚人口结构庞大，65 岁或以上的人口不到 4%。这些情况共同导致肯尼亚医院目前没有因呼吸困难患者而不堪重负。然而，该国实施的严格封锁已将疾病负担转移到由于基本医疗服务中断而造成的孕产妇和儿童死亡。科学，本期第 14 页。 79；另见 p. 27 截至 2020 年 5 月，每 20 名肯尼亚成年人中就有 1 人携带 SARS-CoV-2 抗体，而当时全国报告的 COVID-19 死亡人数还不到 100 例。严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 在非洲的传播情况鲜有报道。肯尼亚于 2020 年 3 月 12 日报告了第一例 SARS-CoV-2 病例，预计病例和死亡人数将达到绝大多数，但截至 2020 年 7 月 31 日，仅有 20,636 例病例和 341 例死亡。然而，社区中 SARS-CoV-2 暴露的程度仍不清楚。我们确定了 2020 年 4 月至 6 月肯尼亚献血者中抗 SARS-CoV-2 免疫球蛋白 G 的患病率。粗血清患病率为 5.6%（3098 名献血者中有 174 名）。人口加权、测试表现调整后的全国血清流行率为 4.3%（95% 置信区间，2.9% 至 5.8%），蒙巴萨城市县最高（8.0%）。0%）、内罗毕（7.3%）和基苏木（5.5%）。 SARS-CoV-2 暴露范围比基于病例的监测显示的范围更广泛，这些结果将有助于指导肯尼亚和整个非洲的大流行应对工作。